In 2016, the only first-line systemic therapy for unresectable HCC approved by the Food and Drug Administration was sorafenib, which is a multi-targeted oral small-molecule tyrosine kinase inhibitor (TKI) that can curb cell proliferation of the tumor cell via inhibiting the activity of Raf-1, B-Raf, and kinases in the Ras/Raf/MEK/ERK signaling pathway. The gene discussed is RAF1; the disease is neoplasm.